Curaleaf International has announced its rebrand into the European cannabis market, driven by the liberalisation of cannabis across Europe.
Formerly EMMAC Life Sciences Group, Curaleaf International, part of Curaleaf Holdings, has announced its official rebrand to the European market. Building on the momentum within the European medicinal cannabis market, Curaleaf International, which has two operating EU-GMP processing facilities and import and distribution capabilities in place in the UK and Germany, says that it expects to see significant regulatory change across Europe for recreational cannabis over the coming years.
Curaleaf International CEO, Antonio Costanzo, commented: “We have seen good growth in medicinal cannabis across Europe, and building on this momentum, the official launch of Curaleaf International has been designed to create a European cannabis platform to capitalise on the rapidly emerging opportunities that are accelerating in line with regulatory change and cultural acceptance.
“The landscape in Europe is changing and we can see similar clear patterns to the progress in North America for adult use cannabis. As the only established fully integrated cannabis company in Europe, our first-mover advantage gives us complete control over the supply chain, and this, coupled with our science-led approach leaves Curaleaf International best positioned to capitalise on this potentially enormous market.”
Since the UK’s decision to legalise medical cannabis in 2018, Curaleaf has seen rapid growth in revenues, and its cannabis flower products and extracted cannabis-based products now supply five separate markets. Over the last 12 months in the UK, the number of patients using its products has increased fivefold.
[activecampaign form=31]
